Given the immunocompromised state of patients due to both the underlying disease and long-term BTK inhibitor therapy, adherence to the HLH-94 (dexamethasone + etoposide) or HLH-2004 protocols may increase the risk of severe infections. The gene discussed is BTK; the disease is infection.